8-K: GRI Bio Reports Positive Phase 2a IPF Data, Nasdaq Compliant

GRI Bio announced additional positive Phase 2a clinical trial data for GRI-0621 in Idiopathic Pulmonary Fibrosis, reinforcing its disease-modifying mechanism, and confirmed its stockholders' equity exceeds Nasdaq's minimum requirement.

Summary

• Additional positive flow cytometry data from the Phase 2a GRI-0621-IPF-02 clinical trial for Idiopathic Pulmonary Fibrosis (IPF) was announced.
• Immune cell samples from lung bronchoalveolar lavage (BAL) fluid and peripheral blood mononuclear cells (PBMC) demonstrated iNKT inhibition and an immunomodulatory shift towards an anti-fibrotic profile.
• GRI-0621 treatment led to increased anti-fibrotic interferon-gamma (IFN-) and reduced pro-fibrotic interleukin-4 (IL-4), IL-13, IL-17A, IL-22, and transforming growth factor-beta (TGF-).
• TCR expression increased after 12 weeks of GRI-0621 treatment compared to baseline or placebo-treated subjects receiving standard of care.
• TGFwas observed to be reduced after 12 weeks of GRI-0621 treatment in T cell subsets (e.g., Treg and Treg-like), B cells, monocytes, macrophages, and neutrophils in BAL and PBMC samples.
• The study previously met its primary endpoint, demonstrating a favorable safety and tolerability profile.
• Secondary endpoints suggested disease-modifying activity, reversal of fibrosis, and inducement of a lung repair mechanism.
• Exploratory endpoints demonstrated increased forced vital capacity (FVC), with twice as many subjects observed to have no decline in FVC compared to standard of care alone at 12 weeks of treatment.
• The Phase 2a study enrolled 35 subjects with IPF, randomized in a 2:1 ratio for GRI-0621 4.5mg or a placebo, with once daily oral administration for 12 weeks.
• A sub-study examined the number and activity of immune cells in bronchoalveolar lavage (BAL) fluid in 8 subjects.
• The Company's stockholders' equity is in excess of the minimum $2.5 million Nasdaq requirement, following a public offering completed in December 2025.

Sentiment

Score: 8

Explanation: The announcement of additional positive Phase 2a clinical data for GRI-0621 in IPF, confirming a disease-modifying mechanism and improved lung function, is a significant positive for a clinical-stage biotech. Coupled with the confirmation of Nasdaq compliance regarding stockholders' equity, the overall sentiment is strongly positive, indicating progress in both clinical development and financial stability.

Positives

• Additional positive flow cytometry data from the Phase 2a clinical trial for GRI-0621 in Idiopathic Pulmonary Fibrosis (IPF).
• Data confirms a disease-modifying mechanism, reinforcing earlier signals of fibrosis resolution, lung repair, and improved lung function.
• GRI-0621 demonstrated iNKT inhibition and an immunomodulatory shift towards an anti-fibrotic profile, increasing anti-fibrotic IFNand reducing pro-fibrotic IL-4, IL-13, IL-17A, IL-22, and TGF-.
• Increased TCR expression observed after 12 weeks of treatment compared to baseline or placebo.
• The study met its primary endpoint for safety and tolerability, differentiating it from existing treatment options.
• Secondary endpoints indicated disease-modifying activity, reversal of fibrosis, and inducement of lung repair.
• Exploratory endpoints showed increased forced vital capacity (FVC), with twice as many subjects having no decline in FVC compared to standard of care alone at 12 weeks.
• Stockholders' equity exceeds the minimum $2.5 million Nasdaq requirement following a December 2025 public offering.

Risks

• Inability to maintain the listing of common stock on The Nasdaq Capital Market and comply with applicable listing requirements, including as a result of the Staff's potential determination that the Company does not satisfy Nasdaq's stockholder equity requirements (notice received November 2025) and any failure to comply with Nasdaq's $1.00 minimum bid price rule.
• Changes in applicable laws or regulations.
• Inability to raise financing in the future.
• Uncertainty regarding the success, cost, and timing of product development activities.
• Inability to obtain and maintain regulatory clearance or approval for products, and any related restrictions and limitations of any cleared or approved product.
• Inability to identify, in-license, or acquire additional technology.
• Inability to compete with other companies currently marketing or engaged in the development of products and services that the Company is currently developing.
• Later data or clinical trials may be inconsistent with or contrary to data and observations to date, including that later data may not indicate a proof-of-concept or patient benefit.
• Inaccuracy in estimates regarding expenses, future revenue, capital requirements, and needs for and the ability to obtain additional financing.
• Inability to protect and enforce its intellectual property portfolio, including any newly issued patents and its ability to obtain any expected patent term extensions, adjustments, exclusivities, or disclaimers.

Future Outlook

The company expects to continue development and commercialization of its product candidates, with ongoing clinical trials. GRI-0621 is believed to have a compelling profile as both an immunomodulator and an anti-fibrotic agent for IPF. The company is also developing a pipeline of novel type 2 diverse NKT (dNKT) agonists for systemic lupus erythematosus and possesses a library of over 500 proprietary compounds to fuel a growing pipeline.

Management Comments

• "There remains a tremendous unmet need for safe, tolerable, and truly effective treatments for patients suffering from IPF." Marc Hertz, PhD, Chief Executive Officer of GRI Bio.
• "GRI-0621 continues to demonstrate a compelling profile, combining favorable safety and tolerability with a dual mechanism of action as both an immunomodulator and an anti-fibrotic agent." Marc Hertz, PhD, Chief Executive Officer of GRI Bio.
• "Our Phase 2a study was intentionally designed to assess a broad range of clinical, biomarker, and mechanistic endpoints." Marc Hertz, PhD, Chief Executive Officer of GRI Bio.
• "The immune cell data announced today are highly consistent with our earlier findings on collagen turnover, lung tissue repair, and improvements in pulmonary function, further strengthening the overall clinical proof-of-concept for GRI-0621." Marc Hertz, PhD, Chief Executive Officer of GRI Bio.

Industry Context

Idiopathic Pulmonary Fibrosis (IPF) is a serious disease with significant unmet medical need, indicating a large market for effective treatments. GRI Bio's approach targets Natural Killer T (NKT) cells, which are key regulators earlier in the inflammatory cascade, aiming to interrupt disease progression and restore immune system homeostasis. This positions GRI-0621 as a potentially novel oral therapeutic in a field where existing treatments may have limitations in safety, tolerability, or efficacy.

Comparison to Industry Standards

• GRI-0621's safety and tolerability profile is described as "differentiated from that of existing treatment options" for IPF.
• The receptor selectivity of GRI-0621 is consistent with the toxicity profile observed in earlier studies evaluating oral tazarotene in over 1,700 patients treated for up to 52 weeks.

Stakeholder Impact

• Shareholders: Positive impact due to strong clinical trial results, potential for future drug approval, and confirmation of Nasdaq listing compliance, which reduces delisting risk.
• Patients (IPF): Potential for a new, safe, and effective treatment option for a serious disease with unmet needs.
• Employees: Positive outlook due to clinical progress and financial stability, potentially leading to continued employment and growth opportunities.
• Regulatory Authorities: Continued engagement as the company progresses through clinical development towards potential regulatory approval.

Next Steps

• Continued development and commercialization of product candidates.
• Further clinical trials for GRI-0621.
• Development of a pipeline of novel type 2 diverse NKT (dNKT) agonists for systemic lupus erythematosus.
• Leveraging a library of over 500 proprietary compounds to fuel a growing pipeline.

Key Dates

Recommendation

The additional positive Phase 2a data for GRI-0621 in Idiopathic Pulmonary Fibrosis, particularly the confirmation of a disease-modifying mechanism, fibrosis resolution, lung repair, and improved lung function (FVC), represents a significant de-risking event for the company's lead asset. Meeting both primary and secondary endpoints, along with positive exploratory findings, strengthens the clinical proof-of-concept. Furthermore, the confirmation of Nasdaq compliance regarding stockholders' equity removes a near-term financial overhang. Given the tremendous unmet need in IPF and the compelling profile of GRI-0621, these results suggest strong potential for future development and commercialization, making the stock an attractive investment for long-term growth.

Keywords

Idiopathic Pulmonary Fibrosis, IPF, GRI-0621, Phase 2a, clinical trial, biotechnology, immune cell modulators, NKT cells, anti-fibrotic, immunomodulation, Nasdaq compliance, stockholders equity, biopharmaceutical, rare disease, lung disease